MARIETTA, Ga., May 4, 2011 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane, announced today the launch of AmnioFix™ Nerve Wrap, the Company's latest biologic implant processed to offer surgical and healing options for nerve repair.
Produced from the MiMedx Group's proprietary Purion® process, AmnioFix™ Nerve Wrap is an allograft from amniotic tissue that is utilized for various nerve repair surgical procedures. Parker H. "Pete" Petit, Chairman and CEO, said, "AmnioFix™ Nerve Wrap is another minimally manipulated tissue offering created by our proprietary Purion® process that was developed by Surgical Biologics, a wholly-owned subsidiary of MiMedx that we acquired in January 2011."
For use as an in vivo nerve wrap in peripheral nerve trauma, AmnioFix™ Nerve Wrap provides a protective barrier and contributes to the three phases of the natural healing process. . . inflammatory phase, proliferation phase and remodeling phase.
John Daniel, President and Founder of Surgical Biologics, stated "We are very excited to be pioneering another application for processed amniotic tissue. Ophthalmology was the industry's initial application for processed amniotic tissue. Surgical Biologics is the first and leading company specifically founded to promote the use of amniotic membrane in multiple surgical applications beyond ophthalmology. In addition to our new nerve wrap offering, Surgical Biologics has pioneered amniotic tissue uses in applications such as diabetic wound care, spinal surgery, orthopedics, burns, trauma and others."
Surgical Biologics has been supplying amniotic tissue for over five years with a stellar record of quality and safety. In addition to the MiMedx branded AmnioFix™ and EpiFix™ tissue, Surgical Biologics is also the leadi
|SOURCE MiMedx Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved